A1: 5-Amino-1MQ peptide is used in laboratory studies to investigate NNMT inhibition, NAD-related metabolic pathways, adipocyte biology, and cellular energetics in in vitro, ex vivo, and non-clinical in vivo models
What does this mean for patients & our practice GLP-1 treatment with semaglutide can offer cardiovascular protection beyond pure weight loss, a potentially valuable tool in treating overweight, together with established cardiovascular disease
Among people with no prior substance use disorder, those taking GLP-1 drugs had an 18% lower risk of developing alcohol use disorder, a 25% lower risk of opioid use disorder and an approximately 20% lower risk of cocaine and nicotine dependence
Ozempic is a weekly injectable medication for type 2 diabetes that uses the drug semaglutide, a GLP-1 receptor agonist, as its active ingredient
This small study provides an initial indication that GLP1-receptor agonists may have a future place in management of AUD